Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

Published 2018 View Full Article

Authors

Keywords

Cationic liposomes, TLR agonist, Resiquimod, Vaccine adjuvant, Tuberculosis, Biodistribution

Journal

JOURNAL OF CONTROLLED RELEASE

Volume 291, Issue -, Pages 1-10

Publisher

Elsevier BV

Online

2018-10-04

DOI

10.1016/j.jconrel.2018.10.002

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started